NOT-AT-14-001: Notice of NCCAM's Participation in RFA-HL-14-013 "Technologies To Assess Sleep Health Status in Populations (R43/R44)"

Notice of NCCAM's Participation in RFA-HL-14-013 "Technologies to Assess Sleep Health Status in Populations (R43/R44)"

Notice Number: NOT-AT-14-001

Key Dates
Release Date: September 26, 2013

Related Announcements
RFA-HL-14-013

Issued by
National Center for Complementary and Integrative Health (NCCIH formerly NCCAM)

Purpose

The purpose of this Notice is to inform potential applicants of the National Center for Complementary and Alternative Medicine NCCAM's participation, effective immediately, in RFA-HL-14-013
"Technologies to Assess Sleep Health Status in Populations (R43/R44)".

Accordingly, the following sections of RFA-HL-14-013 have been modified to reflect NCCAM's participation in this funding opportunity announcement.

Part 1. Overview Information

Components of Participating Organizations
National Heart, Lung, and Blood Institute (NHLBI)
National Center for Complementary and Integrative Health (NCCIH formerly NCCAM)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.233, 93.213

Part 2. Section I. Funding Opportunity Description

NCCAM Specific Areas of Research Interest
To stimulate the development of a biomarker index for changes in sleep health associated with co-morbid pain and especially chronic pain. Primary insomnia is associated with reduced pain thresholds and with reduced effectiveness of therapeutic modalities that ameliorate pain. Data also suggest that persistent insomnia, either primary or secondary, is causally related to developing chronic pain. Overall, NCCAM is interested in the development of a biomarker index for changes in sleep health associated with risk of pain-related morbidity and pain-related quality of life. Development may involve existing datasets, new analyses of existing biosamples, or prospective data and sample collection.

Phase I studies should propose strategies to develop planned biomarker indices associated with sleepiness due to acute or chronic sleep deficiency in otherwise healthy middle-age adults, before and during recovery sleep, and to relate these changes to pain thresholds. Phase II studies should propose to fully characterize the performance of planned biomarker indexes in ethnically diverse populations of middle-age patients with sleep disturbances, insomnia, or in those who are shift workers and/or have sleep apnea before and during intensive risk factor modification (i.e., behavioral approaches to stress reduction, enhanced regularity of sleep schedules, improved sleep hygiene, optimal work schedules, CPAP use) and to relate these changes to amelioration of pain and/or enhancement of quality of life.

Funds Available and Anticipated Number of Awards
NCCAM expects to commit (provided application is well-coupled to the specific topic of sleep and pain) $150,000 in total costs for a Phase I award in year FY2014 and $500,000 in total costs for a Phase II award in year FY2015, provided the phase I award has been successful.

Agency Contacts

Scientific/Research Contact
D. Lee Alekel, PhD
National Center for Complementary and Alternative Medicine (NCCAM)
Telephone: 301-443-8374
Email: Lee.Alekel@nih.gov

Financial/Grants Management Contact
George Tucker, MBA
National Center for Complementary and Alternative Medicine (NCCAM)
Telephone: 301-594-9102
Email: tuckerg@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

D. Lee Alekel, PhD
National Center for Complementary and Alternative Medicine (NCCAM)
Telephone: 301- 443-8374
Fax: 301- 480-1587
Email: Lee.Alekel@nih.gov